Supreme court sets aside Myriad gene patent ruling

WASHINGTON Mon Mar 26, 2012 10:26am EDT

Related Topics

WASHINGTON (Reuters) - The Supreme Court set aside on Monday a ruling that Myriad Genetics Inc can patent two genes linked to breast and ovarian cancers, in a case closely watched by the biotechnology industry.

The justices set aside a ruling by the U.S. Court of Appeals for the Federal Circuit that Myriad has the right to patent two human genes, known as BRCA1 and BRCA2, that account for most inherited forms of breast and ovarian cancers, and sent the matter back for more proceedings.

The Supreme Court ordered the further proceedings at the lower court in view of the high court's ruling last week in a case that raised similar issues and that held that companies cannot patent observations about a natural phenomenon.

Women who test positive using Myriad's gene test, called BRACAnalysis, have an 82 percent higher risk of breast cancer and a 44 percent higher risk of ovarian cancer in their lifetimes.

The appeals court by a 2-1 vote ruled the genes isolated by the company can be patented because Myriad is testing for distinctive chemical forms of the genes, and not as they appear naturally in the body.

The dissenting judge said the genes could not be patented just because they were isolated from the body.

The appeals court overturned a ruling by a federal judge in New York that the genes could not be patented, a decision that caused widespread concern for the biotechnology industry. It said such patents were essential to foster innovation.

The patents granted to Myriad give the company the exclusive right to perform the genetic tests. The appeals court in its ruling in July also found that Myriad's method for screening potential therapies can be patented.

The lawsuit filed in 2009 claimed the patents violated patent law, restricting scientific research and patients' access to medical care.

The appeal to the Supreme Court was backed by a number of organizations representing health care professionals, including the American Medical Association, and other groups.

The appeal argued that the question of whether genes and the information they convey can be patented is of "paramount importance to the future of patent law, the advancement of medical science and patients' health."

Myriad opposed the appeal. Its shares rose more than 2 percent after the Supreme Court's order.

The attorney representing the company, Gregory Castanias, told the Supreme Court that patents involving isolated DNA molecules have been issued for nearly 30 years, resulting in significant investment by biotechnology companies.

Castanias said the challenged patents at issue in the case were filed more than 16 years ago. He said the appeals court's decision was correct and the "questions presented are unique to this case, factbound and unlikely to recur."

The Supreme Court case is the Association for Molecular pathology v. Myriad Genetics, No. 11-725.

(Reporting By James Vicini; Editing by Gerald E. McCormick)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
thecrunch wrote:
Actually, compared to women without the gene mutation, those who are BRCA positive have a risk factor that is a whopping 200% greater than the average woman. The statistics that your reporter quoted was the individual lifetime risk for the development of cancer for those with BRCA mutations. About 82% of women with the gene will develop breast cancer and 44% will develop ovarian cancer over their lifetime. If your readers want more information about hereditary breast and ovarian cancer, they may want to check out

Mar 27, 2012 1:07pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.